Ucb S A Stock Price, News & Analysis

UCB (OTC:UCBJY) announced significant long-term efficacy data for BIMZELX® (bimekizumab-bkzx) in treating moderate-to-severe plaque psoriasis. The data, presented at EADV 2025, showed that 48.9% of Week 16 PASI 0 responders maintained complete skin clearance over four years.

Key findings include 81.8% and 82.7% of patients achieving nail matrix and nail bed mNAPSI 0 respectively over three years, and 98.1% of high-risk patients maintaining no PsA symptoms over three years. BIMZELX, as the first and only approved dual IL-17A and IL-17F inhibitor, demonstrated sustained efficacy in preventing disease progression and maintaining complete skin clearance.

UCB (OTC:UCBJY) has released findings from their "Rheum for Improvement" survey, focusing on 250 Gen Z and Millennial patients living with chronic rheumatic diseases. The study revealed that despite feeling misunderstood, 74% of Gen Z and 67% of Millennials are willing to discuss their diagnoses with loved ones.

Key findings highlight that chronic fatigue remains a significant unmet need, affecting 60% of axSpA patients and 36% of PsA patients. Pain management emerged as a primary treatment goal for 80% of participants. The survey also revealed that while many patients feel empowered to participate in treatment decisions, there's still a need for improved HCP awareness and diagnostic tools.

The company's BIMZELX® treatment has shown promising results, with over 40% of patients experiencing significant symptom improvement in clinical studies.

UCB (OTC:UCBJY) will present 26 scientific abstracts at the International Epilepsy Congress (IEC) in Lisbon, focusing on developmental and epileptic encephalopathies (DEEs) and prolonged seizures. Key highlights include a combined open-label extension study of FINTEPLA® (fenfluramine) involving 412 patients with Dravet syndrome or Lennox-Gastaut syndrome, showing sustained benefits and no new safety concerns.

The presentations encompass research on diagnostic challenges in adult DEE patients, caregiver experiences, and the impact of prolonged seizures. Notable findings include a post-hoc analysis supporting the 2-minute cutoff for defining prolonged tonic-clonic seizures, and studies on seizure emergency care pathways. The company will also host a symposium on September 1st focusing on DEEs in adulthood.

UCB (OTC:UCBJY) hosted its 2025 Hidradenitis Suppurativa (HS) Summit on August 1-2, bringing together over 100 participants including patients, healthcare providers, and advocacy groups at its Atlanta campus. The summit focused on patient storytelling, wellness, nutrition, and care advocacy for the HS community.

The event highlighted BIMZELX® (bimekizumab-bkzx), UCB's treatment for moderate-to-severe HS, which demonstrated significant efficacy in clinical trials with approximately 50% of patients seeing a 50% reduction in inflamed nodules and abscesses at 16 weeks, compared to 30% in the placebo group. BIMZELX is notably the first approved treatment specifically targeting both IL-17A and IL-17F cytokines for HS patients.

UCB (OTC:UCBJY) has expanded its "Get Yourself Back" direct-to-consumer campaign for BIMZELX® (bimekizumab-bkzx), targeting the hidradenitis suppurativa (HS) community. BIMZELX, approved in November 2024, is the first and only treatment for moderate-to-severe HS that specifically targets IL-17A and IL-17F cytokines.

The campaign features clinical data showing 48-52% of BIMZELX-treated patients achieved at least a 50% reduction in inflamed nodules and abscesses at 16 weeks, compared to 29-32% for placebo. The initiative includes TV commercials with real patients, educational resources, and the BIMZELX Navigate® support program offering dedicated nurse navigators for prescribed patients.

UCB (OTC:UCBJY) announced positive Phase 3 study results for fenfluramine in treating CDKL5 deficiency disorder (CDD), an ultra-rare developmental and epileptic encephalopathy. The study met its primary endpoint of reducing countable motor seizure frequency and most key secondary endpoints.

The randomized, double-blind trial involved 87 patients aged 1-35 with CDD diagnosis and uncontrolled seizures. CDD affects approximately 1 in 40,000 to 60,000 live births. The drug demonstrated a safety profile consistent with previous studies in Dravet syndrome and Lennox-Gastaut syndrome. UCB plans to pursue regulatory approval for this potential new treatment option.

UCB announced its participation in the UMDF Mitochondrial Medicine 2025 Conference, presenting three key research posters on thymidine kinase 2 deficiency (TK2d). The presentations include findings from disease course studies in untreated patients, examining progression and outcomes over time, as well as insights into caregiver burden from the Assessment of TK2d Patient Perspectives study. The research focuses on both pediatric (≤12 years) and adult (>12 years) onset patients, representing data from the largest international TK2d dataset. Dr. Kimberly A. Moran, SVP & Head of US Rare Diseases at UCB, emphasized the company's commitment to advancing understanding of this rare mitochondrial disease, which has historically lacked research attention.

UCB has awarded 15 scholarships to individuals affected by myasthenia gravis (MG) in the U.S. through its inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship program. The recipients include both people living with MG and caregivers, with one-third being high school seniors and others pursuing undergraduate, graduate degrees, or certification programs. The selection committee comprised medical professionals and people impacted by MG. Kim Moran, SVP & Head of U.S. Rare Diseases at UCB, announced that the scholarship program will continue into 2026. The initiative demonstrates UCB's commitment to supporting the rare disease community beyond medical treatment by helping recipients manage educational costs and advance their career goals.

UCB (UCBJY) has announced plans to build a new state-of-the-art biologics manufacturing facility in the United States, representing a major expansion of its U.S. presence. The investment is expected to generate an economic impact of approximately $5 billion and create 300 permanent high-skilled jobs plus 500 construction positions. Since 2017, UCB has grown its U.S. workforce by 73% to 2,000 employees and invested $4.5 billion in acquisitions and capital improvements. The company has achieved 15 FDA approvals or indication expansions, with 8 occurring in the past two years. The new facility aims to serve UCB's growing U.S. patient base while strengthening its global supply chain. The company is currently conducting a feasibility study to determine the optimal location, focusing on areas with strong talent pipelines and innovation ecosystems.